Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2010

View Archived Issues

New mechanism of action of AN-3365 linked to potent activity in Gram-negative bacterial infections

AVL-292 shows promise in models of arthritis and cancer and enters clinical development

Lipideon Biotechnology claims new cholesterol absorption inhibitors

Novartis discontinues development of albinterferon alfa-2b and Mycograb

Phase II data reported on Cevira in patients with mild cervical abnormalities

Zabofloxacin shows cardiac safety in phase I trial in healthy subjects

AS-2041835 and micafungin show synergistic antifungal activity in preclinical study

Phase II rasagiline trial in parkinsonian multiple system atrophy / News in Context

Daiichi Sankyo launches gel formulation of Loxonin in Japan

Lundbeck acquires exclusive rights to KW-6356 from Kyowa Hakko Kirin

Brain Factory gains Japanese rights to Eisai's ravuconazole prodrug

Human Genome Sciences and Novartis halt Zalbin development for HCV infection

Reviva Pharma claims new ligands of dopamine D2 receptor and serotonin receptors 5-HT1A/2A

Ambit Biosciences presents new inhibitors of JAK2 and JAK3

Pfizer describes new antagonists of calcium-sensing CaS receptor

Glenmark Pharma identifies new TRPM8 channel antagonists

FDA extends Xifaxan sNDA PDUFA goal date by 3 months

ProteoTech and Tasly collaborate on Exebryl-1 for Alzheimer's disease

Teva provides update on status of BLA for Neutroval in neutropenia

FDA approves Kapvay for use with stimulant medication for ADHD

Meda acquires erectile dysfunction therapy Muse from Vivus

Noven acquires Daytrana methylphenidate transdermal system from Shire

Enrollment complete for phase III trial of AG200-15 contraceptive patch

DSP and SanBio develop new stem cell therapy for stroke

Evotec and Shionogi form multiple-target drug discovery alliance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...